News headlines about NuVasive (NASDAQ:NUVA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuVasive earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 46.5477964101867 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Stryker, NuVasive, Medtronic & more: 11 device company notes (beckersspine.com)
- NuVasive announces leadership changes in finance team (smartbrief.com)
- Nuvasive (NUVA) Shares Cross Above 200 DMA (nasdaq.com)
- NuVasive launches AttraX scaffold bone graft biologic (massdevice.com)
- Global Spinal Fusion Market 2018 Key Players: Medtronic, Stryker Corporation, Zimmer Biomet, Orthofix Interntional, NuVasive, Inc. (openpr.com)
Several equities research analysts have recently commented on NUVA shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $55.00 target price (down from $67.00) on shares of NuVasive in a report on Tuesday, February 27th. BidaskClub raised NuVasive from a “strong sell” rating to a “sell” rating in a research report on Friday, March 2nd. Cowen set a $62.00 price target on NuVasive and gave the company a “buy” rating in a research report on Tuesday, February 27th. ValuEngine lowered NuVasive from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Finally, Zacks Investment Research raised NuVasive from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research report on Monday, February 19th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. NuVasive has a consensus rating of “Hold” and a consensus price target of $65.06.
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Tuesday, May 1st. The medical device company reported $0.39 EPS for the quarter, missing the Zacks’ consensus estimate of $0.45 by ($0.06). NuVasive had a return on equity of 13.14% and a net margin of 4.14%. The firm had revenue of $260.50 million during the quarter, compared to the consensus estimate of $259.43 million. During the same quarter in the prior year, the business posted $0.37 EPS. NuVasive’s revenue was up 4.6% compared to the same quarter last year. analysts anticipate that NuVasive will post 2.45 EPS for the current year.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.